Pre-Surgery Immunotherapy Delivers Long-Term Cancer-Free Survival for Colorectal Cancer Patients
A groundbreaking clinical trial led by UK researchers has revealed that a short course of immunotherapy before surgery can produce remarkable results for patients with a specific type of colorectal cancer. Those who received just nine weeks of pembrolizumab prior to their operation have remained cancer-free for nearly three years—an outcome that challenges the traditional approach of surgery followed by months of chemotherapy. This Q&A explores the key findings and implications of this breakthrough study.
What is the breakthrough described in this colorectal cancer study?
The breakthrough involves a new treatment strategy for patients with mismatch repair deficient (dMMR) colorectal cancer, a subtype that is often less responsive to standard chemotherapy. In a UK-led clinical trial, patients received a short burst of the immunotherapy drug pembrolizumab (Keytruda) for nine weeks before undergoing surgery. Remarkably, nearly three years later, these patients have remained cancer-free. This result is striking because it suggests that a brief pre-operative immunotherapy regimen may be more effective than the standard approach of surgery followed by months of chemotherapy. The study was small but has generated significant excitement among oncologists, as it could dramatically change treatment protocols for this patient group.
How does this trial design differ from the standard treatment for colorectal cancer?
Traditionally, patients with colorectal cancer undergo surgery first to remove the tumor, then receive several months of adjuvant chemotherapy to eliminate any remaining cancer cells. This trial flipped that sequence: patients received pembrolizumab for nine weeks before surgery, with no additional chemotherapy afterward. The standard approach often involves aggressive chemo, which can cause severe side effects like fatigue, nausea, and neuropathy. In contrast, the pre-surgery immunotherapy regimen was well tolerated. The trial’s design was based on the hypothesis that priming the immune system (see question 3) before removing the tumor could allow it to attack cancer cells more effectively. The nearly three-year cancer-free survival rate suggests this hypothesis may be correct, potentially sparing patients from long, grueling chemotherapy cycles.
What is pembrolizumab and how does it work as an immunotherapy?
Pembrolizumab, marketed as Keytruda, is a PD-1 inhibitor, a type of immunotherapy that helps the body’s immune system recognize and attack cancer cells. Cancer cells often hide by expressing a protein called PD-L1, which binds to PD-1 receptors on T-cells, effectively turning off the immune response. Pembrolizumab blocks this interaction, “releasing the brakes” on T-cells, allowing them to seek out and destroy tumor cells. In the context of dMMR colorectal cancer, these tumors have many genetic mutations, making them more visible to the immune system once PD-1 is blocked. By giving the drug before surgery, the immune system can target the primary tumor and potentially any micrometastases, reducing the risk of recurrence. This mechanism explains why the short treatment course produced such durable responses.
Why is giving immunotherapy before surgery considered a game-changer?
Administering immunotherapy before surgery, known as neoadjuvant therapy, has several advantages. First, it allows oncologists to shrink the tumor before removal, making surgery easier and more likely to be successful. Second, it uses the intact tumor as a source of antigens to stimulate a powerful immune response, which may help eliminate cancer cells that have spread elsewhere. Third, for dMMR colorectal cancer, this approach appears to be extremely effective—the trial found that nearly all patients had a major pathological response, meaning very few cancer cells remained in the surgical specimen. Finally, it spares patients from months of post-surgery chemotherapy, which can be debilitating. This shift in treatment sequence could not only improve outcomes but also quality of life for many patients. The nearly three-year cancer-free results add weight to this paradigm shift.
How long have patients remained cancer-free after this treatment?
According to the study results, patients who received the nine-week course of pembrolizumab before surgery have remained cancer-free for nearly three years. Specifically, at the time of reporting, no patient had experienced a recurrence of their colorectal cancer. This is a remarkable outcome, especially considering that many patients in the trial had advanced or high-risk tumors. While longer follow-up is needed to confirm durability, the three-year milestone is highly encouraging. In standard treatment, patients with similar cancer stages often face a significant risk of relapse within the first few years, even after surgery and chemo. The fact that this immunotherapy-first approach has produced such a sustained response suggests it may offer a potential cure for some patients. Researchers are now planning larger studies to validate these findings.
What type of colorectal cancer does this immunotherapy target, and who is eligible?
This breakthrough specifically applies to patients with mismatch repair deficient (dMMR) colorectal cancer, also known as microsatellite instability-high (MSI-H) tumors. This subtype accounts for about 15% of all colorectal cancers. dMMR tumors have defects in the DNA repair system, causing many mutations that make them highly visible to the immune system—hence the strong response to PD-1 inhibitors like pembrolizumab. Eligibility for this trial included patients with locally advanced dMMR colorectal cancer who were candidates for surgery. However, not all colorectal cancer patients will benefit; those with mismatch repair proficient (pMMR) tumors, the majority, do not respond as well to immunotherapy alone. Therefore, genetic testing of the tumor is essential to identify candidates for this approach. The study highlights the importance of personalized medicine in cancer treatment.
What are the implications for standard treatment protocols and future research?
The success of this trial is likely to accelerate changes in clinical guidelines for dMMR colorectal cancer. Currently, surgery followed by adjuvant chemotherapy is standard, but this data strongly supports considering neoadjuvant immunotherapy instead. The next steps involve larger phase III trials to confirm the benefits and to compare this approach directly with conventional therapy. Additionally, researchers will explore whether shorter or different courses of immunotherapy could be just as effective, and whether this strategy could work for other cancer types. The trial also raises questions about the role of chemotherapy—if patients can achieve cancer-free status with immunotherapy alone before surgery, chemotherapy may become unnecessary for some. This shift could reduce side effects and healthcare costs. However, long-term data on overall survival and potential late effects are still needed. The field is now focused on optimizing the timing and duration of immunotherapy for maximum benefit.
Are there any side effects or risks associated with this pre-surgery immunotherapy approach?
Like all cancer treatments, pembrolizumab can cause side effects, though they were generally manageable in this trial. Common side effects include fatigue, rash, and infusion reactions. More serious immune-related side effects, such as colitis, pneumonitis, or thyroid dysfunction, can occur but were infrequent. Importantly, because the treatment course was short (only nine weeks), the risk of cumulative toxicity was lower than with prolonged immunotherapy or lengthy chemotherapy. Additionally, because surgery was performed soon after the last dose, any acute side effects could be monitored closely. No treatment-related deaths were reported. Patients did not need post-operative chemotherapy, sparing them from its typical side effects like nausea, nerve damage, and bone marrow suppression. However, as with any new approach, long-term follow-up is necessary to detect any delayed adverse effects. Overall, the risk-benefit profile appears favorable for this select patient group.